T 301-255-0524
F 301-230-2891
E kmarshall@shulmanrogers.com
Clients consistently praise Keith Marshall for his hard work and dedication to helping them achieve their business objectives. An associate in the Business and Financial Services Department, Keith represents clients in the software, technology, media, and other industries in connection with M&A transactions, joint ventures, private equity investments, financing and other transactional matters.
I couldn’t have been more pleased with the savvy advice and results-driven leadership that Shulman Rogers provided in a critical two-pronged deal for us. Aaron Ghais and Keith Marshall brought strong judgment, creativity, and a collaborative approach to spearhead the completion of an industry-changing acquisition. I’d happily refer this team to anyone who asked!
-Sean Cercone, CEO/President, Broadway Licensing
Prior to joining Shulman Rogers, Keith was an associate in the Washington, DC offices of Dow Lohnes PLLC and Cooley LLP. Prior to entering into private practice, he completed a fellowship with AARP’s Legal Counsel for the Elderly, assisting clients with bankruptcy and consumer debt issues, public benefit concerns, deed changes and other legal problems. Keith has also represented clients pro bono before the Social Security Administration in connection with continuing disability determinations and appeals of disability benefit terminations.
May 4, 2020
In this second alert in our series discussing M&A in the COVID-19 era, we will address potential acquirers in the marketplace. As we posited in our last release, the COVID-19 pandemic will most certainly create opportunities for buyers poised to act fast to seize good deals when they arise.
April 24, 2020
We are now more than a month into the U.S. COVID-19 shutdown and several months into the broader global crisis. The impact on U.S. and global M&A activity has been both sudden and severe. Global M&A for Q1 2020 is down 33% as compared to Q1 2019; and the value of announced mergers in the U.S. is down more than 50%.
July 1, 2021
Shulman Rogers’ Mergers and Acquisitions team was pleased to support our client, U.S.-based gene therapy contract development and manufacturing organization, Vigene Biosciences, in their recent agreement to be acquired by Charles River Laboratories for up to $350 million.
March 30, 2021
Shulman Rogers was pleased to provide counsel to Broadway Licensing in its acquisition of Dramatists Play Service.
October 19, 2020
POTOMAC, MD. October 19, 2020 – Press Ganey recently announced the expansion of its health care consumerism platform with the acquisition of Doctor.com.
December 2, 2016
Shulman Rogers represented Vigene Biosciences, Inc., a leading biotechnology company for viral vector production and development located in Rockville, Maryland […]